Atara ‘all in’ on allogeneic treatments

You are here: Home > Biotech > Current Article

By Marissa Nall / Friday, November 15th, 2019 / Comments Off on Atara ‘all in’ on allogeneic treatments

Atara Biotherapeutics redirected its focus toward its pipeline of treated donor cell therapies in the second half of 2019, while it continues its search to fill three top roles. The shift in priority was the first sign of a company “going all in” on an allogeneic treatment for multiple sclerosis, said Salim Syed, senior biotech…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.